ArticleMedicine2026
Study on diagnostic genes and immune microenvironment disorder in comorbid atherosclerosis and Alzheimer disease.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) and Alzheimer disease (AD) are globally prevalent chronic diseases with challenges of difficult early diagnosis and a lack of effective combined therapies. This study explored their shared molecular mechanisms, potential diagnostic biomarkers, and immune microenvironment disorders. Using AS dataset GSE100927 and AD dataset GSE97760, key differentially expressed genes (key DEGs) were identified via bioinformatics (differential expression analysis, protein-protein interaction network, machine learning). A risk prediction model was built and validated with receiver operating characteristic/area under the curve. Immune infiltration was compared between patient and control groups; miRNA-transcription factor-mRNA and key DEGs-chemical networks were predicted, and key DEGs-AS/AD causal relationships verified by Mendelian randomization. Venn analysis found 89 common DEGs (enriched in lipid metabolism, Wnt pathway, etc). Four key DEGs (early growth response 2 [EGR2], leukocyte-specific transcript 1 [LST1], membrane-spanning 4-domains subfamily A member 7 [MS4A7], and 2'-5'-oligoadenylate synthetase like [OASL]) were confirmed. The model had high accuracy (C-index = 0.982, area under the curve > 0.9). Mendelian randomization showed EGR2 was an AS risk/AD protective factor; LST1 an AS risk factor; MS4A7 an AD risk factor; no clear OASL-AD causality. EGR2, LST1, MS4A7, and OASL are novel diagnostic biomarkers and potential therapeutic targets for comorbid AS and AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.